Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Dec 1;102(11):1535-9.
doi: 10.1016/j.amjcard.2008.07.041. Epub 2008 Sep 18.

Usefulness of immunosuppression for giant cell myocarditis

Leslie T Cooper Jr  1 , Joshua M Hare, Henry D Tazelaar, William D Edwards, Randall C Starling, Mario C Deng, Santosh Menon, G Martin Mullen, Brian Jaski, Kent R Bailey, Madeleine W Cunningham, G William Dec; Giant Cell Myocarditis Treatment Trial Investigators
Collaborators, Affiliations
Clinical Trial

Usefulness of immunosuppression for giant cell myocarditis

Leslie T Cooper Jr et al. Am J Cardiol. .

Abstract

Giant cell myocarditis (GCM) is a rare and highly lethal disorder. The only multicenter case series with treatment data lacked cardiac function assessments and had a retrospective design. We conducted a prospective, multicenter study of immunosuppression including cyclosporine and steroids for acute, microscopically-confirmed GCM. From June 1999 to June 2005 in a standard protocol, 11 subjects received high dose steroids and cyclosporine, and 9 subjects received muromonab-CD3. In these, 7 of 11 were women, the mean age was 60 +/- 15 years, and the mean time from symptom onset to presentation was 27 +/- 33 days. During 1 year of treatment, 1 subject died of respiratory complications on day 178, and 2 subjects received heart transplantations on days 2 and 27, respectively. Serial endomyocardial biopsies revealed that after 4 weeks of treatment the degree of necrosis, cellular inflammation, and giant cells decreased (p = 0.001). One patient who completed the trial subsequently died of a fatal GCM recurrence after withdrawal of immunosuppression. Her case demonstrates for the first time that there is a risk of recurrent, sometimes fatal, GCM after cessation of immunosuppression. In conclusion, this prospective study of immunosuppression for GCM confirms retrospective case reports that such therapy improves long-term survival. Additionally, withdrawal of immunosuppression can be associated with fatal GCM recurrence.

Trial registration: ClinicalTrials.gov NCT00027443.

PubMed Disclaimer

Conflict of interest statement

Disclosures: None of the Authors have any conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Average histologic scores by blinded analysis at baseline and day 30 in subjects enrolled in the GCM Treatment Trial.* p<0.001, †p=0.43, ‡p=0.01
Figure 2
Figure 2
Representative histologic findings of widespread inflammatory infiltrate including giant cells at baseline (2a) is largely resolved with some replacement fibrosis after 30 days of therapy (2b). Hematoxylin and Eosin 100x.
Figure 2
Figure 2
Representative histologic findings of widespread inflammatory infiltrate including giant cells at baseline (2a) is largely resolved with some replacement fibrosis after 30 days of therapy (2b). Hematoxylin and Eosin 100x.
Figure 3
Figure 3
Change in ejection fraction for 10 subjects with baseline and 30 day assessments. p=NS
See this image and copyright information in PMC

References

    1. Costanzo-Nordin M, Silver M, O’Connell J, Scanlon P, Robinson J. Giant Cell Myocarditis: dramatic hemodynamic histologic improvement with immunosuppressive therapy. Eur Heart J. 1987;(Suppl J):271–274. - PubMed
    1. Cooper LT, Jr, Berry GJ, Rizeq M, Schroeder JS. Giant cell myocarditis. J Heart Lung Transplant. 1995;14:394–401. - PubMed
    1. Cooper LT, Berry GJ, Shabetai R. Giant Cell Myocarditis: Natural History and Treatment. N Engl J Med. 1997;336:1860–1866. - PubMed
    1. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990;57:250–262. - PubMed
    1. Kodama M, Matsumoto Y, Fujiwara M. In vivo lymphocyte-mediated myocardial injuries demonstrated by adoptive transfer of experimental autoimmune myocarditis. Circulation. 1992;85:1918–1926. - PubMed

Publication types

MeSH terms

Associated data